AKT2在非小细胞肺癌中的表达及预后价值
[Expression and prognostic value of AKT2 in non-small cell lung cancer].
作者信息
Miao Xiaohui, Song Yong, Lv Tangfeng, Zhan Ping, Lv Yanling, Yuan Dongmei
机构信息
Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2011 May;14(5):396-9. doi: 10.3779/j.issn.1009-3419.2011.05.03.
BACKGROUND AND OBJECTIVE
AKT2 is a critical actor in the PI3K signal transduction pathway. Activation of AKT2 can lead to cell growth and survival. It has been revealed that AKT2 play a central role in tumorigenesis, tumor growth as well as metastasis. The aim of this study is to investigate the association between AKT2 and the clinical outcome of non-small cell lung cancer (NSCLC) patients by detecting its expression levels in the tumor tissue samples.
METHODS
We developed an immunohistochemistry (IHC) assay to measure AKT2 protein levels in lung specimens from 80 cases with NSCLC and 10 cases with benign pulmonary disease.
RESULTS
The positive rate of AKT2 was 57.50% (46/80) in NSCLC, which was higher than that in benign pulmonary (10.0%) samples (Chi-square=8.038, P=0.006). There was no significant correlation between AKT2 expression and the clinicopathologic profiles. The expression of AKT2 was significantly correlated with the progression free survival (PFS) (Chi-square=12.671, P=0.005) and the overall survival (OS) (Chi-square=9.851, P=0.021) of patients with NSCLC.
CONCLUSION
AKT2 may provide a prognostic bio-marker of NSCLC.
背景与目的
AKT2是PI3K信号转导通路中的关键因子。AKT2的激活可导致细胞生长和存活。研究表明，AKT2在肿瘤发生、肿瘤生长以及转移过程中发挥核心作用。本研究旨在通过检测非小细胞肺癌（NSCLC）患者肿瘤组织样本中AKT2的表达水平，探讨其与NSCLC患者临床预后的相关性。
方法
我们开发了一种免疫组织化学（IHC）检测方法，用于检测80例NSCLC患者和10例良性肺部疾病患者肺标本中AKT2蛋白水平。
结果
NSCLC中AKT2的阳性率为57.50%（46/80），高于良性肺部疾病样本中的阳性率（10.0%）（卡方检验=8.038，P=0.006）。AKT2表达与临床病理特征之间无显著相关性。AKT2表达与NSCLC患者的无进展生存期（PFS）（卡方检验=12.671，P=0.005）和总生存期（OS）（卡方检验=9.851，P=0.021）显著相关。
结论
AKT2可能是NSCLC的一种预后生物标志物。
Zotero 插件